WithdrawnNot Applicable

MATERNAL AND NEONATAL SCREENING FOR GROUP B STREPTOCOCCI : A Follow up STUDY

Stopped: COVID 19 Pandemic disabled team involved

Egypt0Started 2019-06-01

Plain-language summary

Group B Streptococcus (GBS), is a facultative gram positive diplococcus originally known for causing bovine mastitis and was not demonstrated to be a human pathogen until 1938. In the 1970s, GBS emerged as the leading cause of neonatal morbidity and mortality, with a frequency of 2-3 cases per 1,000 live births and case-fatality ratios as high as 50%

Who can participate

Age range18 Years – 46 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * pregnant females 35-37 weeks of gestational age Patients who were followed till delivery without prolonged rupture of membrane Exclusion Criteria: * patients lost follow up and or had prolonged rupture of membrane\>12 hours

What they're measuring

prevalence of GBS in Fayoum

Timeframe: one year

Trial details

NCT IDNCT04227730

SponsorFayoum University Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2020-12-30

View on ClinicalTrials.gov More Group B Streptococcal Infection trials